Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS -0.80%80 Cash-to-Debt is 14.86 as of Dec. 2025, which is 36% above its 10-year median of 10.92. GuruFocus rates ASX:VLS with a GF Score™ of 80/100 and a GF Value™ of A$2.50 (Fairly Valued). The stock has 1 warning sign investors should review. Among 985 Drug Manufacturers companies, Vita Life Sciences ranks better than 79.19% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vita Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2025 was 14.86.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vita Life Sciencescould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Vita Life Sciences's Cash-to-Debt or its related term are showing as below:
ASX:VLS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.83 Med: 10.92 Max: 113.26
Current: 14.86
During the past 13 years, Vita Life Sciences's highest Cash to Debt Ratio was 113.26. The lowest was 3.83. And the median was 10.92.
ASX:VLS's Cash-to-Debt is ranked better than 79.19% of 985
companies
in the Drug Manufacturers industry
Industry Median: 1
vs ASX:VLS: 14.86
Vita Life Sciences (ASX:VLS) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Vita Life Sciences Cash-to-Debt Related Terms
Vita Life Sciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a Cash-to-Debt of 14.86 as of Dec. 2025. This is 36% above median its historical median of 10.92. Over the past decade, Vita Life Sciences' Cash-to-Debt has ranged from 3.83 to 113.26. According to the industry distribution chart, Vita Life Sciences ranks #205 out of 985 companies in the Drug Manufacturers industry, placing it in the top 20.8%.
Is Vita Life Sciences' Cash-to-Debt too high?
Vita Life Sciences' current Cash-to-Debt of 14.86 is 36% above median its 10-year median of 10.92. Over the past 10 years, this metric has ranged from a low of 3.83 to a high of 113.26. The Drug Manufacturers industry median Cash-to-Debt is 1.00. Vita Life Sciences' value of 14.86 is 1386% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #205 out of 985 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #205 out of 985 companies for Cash-to-Debt. This places Vita Life Sciences in the top 21% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.00. Vita Life Sciences' value of 14.86 is 1386% above this benchmark. Historically, Vita Life Sciences' own Cash-to-Debt has ranged from 3.83 to 113.26 over the past decade. While the company's 10-year median is 10.92 vs. the industry median of 1.00, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 1.00, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Cash-to-Debt of 14.86 is 1386% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 1.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Cash-to-Debt is 14.86, which is 36% above median its own 10-year median of 10.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.50, compared to a current price of A$2.48 — trading 0.8% below its estimated fair value. The current Cash-to-Debt is 14.86, which is 36% above median its 10-year median of 10.92 and 1386% above the Drug Manufacturers industry median of 1.00. Vita Life Sciences' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Cash-to-Debt is 14.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.48 is trading 0.8% below its estimated GF Value™ of A$2.50.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Cash-to-Debt: 14.86 (36% above median its 10-year median of 10.92)
GF Value™: A$2.50 vs. price of A$2.48 (0.8% below fair value)
Industry Position: 1386% above the Drug Manufacturers median (#205 of 985)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
80GF Score
Get the complete analysis for ASX:VLS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
